SpyGlass Ophthalmics
SpyGlass Ophthalmics
  • Home
  • About Us
  • Contact Us
    • Home
    • About Us
    • Contact Us
  • Home
  • About Us
  • Contact Us

Welcome to SpyGlass Ophthalmics

Welcome to SpyGlass OphthalmicsWelcome to SpyGlass OphthalmicsWelcome to SpyGlass Ophthalmics

A vision towards a higher quality of life!

Welcome to SpyGlass Ophthalmics

Welcome to SpyGlass OphthalmicsWelcome to SpyGlass OphthalmicsWelcome to SpyGlass Ophthalmics

A vision towards a higher quality of life!

SpyGlass Ophthalmics NEWS

January 2021: SpyGlass Ophthalmics secures Series B financing

January 2021: SpyGlass Ophthalmics secures Series B financing

January 2021: SpyGlass Ophthalmics secures Series B financing

SpyGlass Ophthalmics (SGO), a privately-held ophthalmic therapeutics company announced  that it has secured $27.5 million in Series B financing. The financing, which was led by Vensana Capital alongside existing investor New Enterprise Associates (NEA), will enable the company to further advance development efforts of platform technology that has the potential to address several unmet needs across a range of chronic ophthalmic diseases. 

May 2019: SpyGlass Ophthalmics secures Series A financing

January 2021: SpyGlass Ophthalmics secures Series B financing

January 2021: SpyGlass Ophthalmics secures Series B financing

SpyGlass Ophthalmics (SGO) has partnered with New Enterprise Associates (NEA) to support the development of novel technologies with a vision towards a higher quality of life.  The funding will be used to achieve SGO’s  research, development and clinical targets.  


Copyright © 2019 SpyGlass Ophthalmics - All Rights Reserved.

Powered by GoDaddy Website Builder